Comparison of Apolipoprotein B/A1 ratio, Framingham risk score and TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention

Min Tian¹,², Rui Li¹,², Zhilei Shan³, Dao Wen Wang¹,², Jiangang Jiang¹,²* and Guanglin Cui¹,²,³*

Abstract

Background: Apolipoproteins (Apo) are known atherogenic factors that play important roles in many mechanisms related to coronary heart disease (CHD). However, it is unclear whether the apoB/apoA1 ratio is an equal or a better predictor than the Framingham Risk Score or TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention.

Methods: We investigated the association between Apolipoprotein B/A1 ratio and cardiovascular risk factors as well as the severity of CHD in 2256 Han Chinese patients. The potential of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c were assessed as a marker to predict cardiovascular adverse events in a prospective subgroup of 1639 CHD patients during a 5-year follow-up.

Results: In the multivariate model, adjusted odds ratios (ORs) were significant for 3-VD vs. 1-VD (OR = 2.36; 95% CI: 1.65–3.38, for the fourth vs. first quartile; P<0.001). The subgroup analysis showed that patients with a higher ApoB/ApoA1 ratio had an increased risk of developing multi-branch lesions and potentially suffer more cardiovascular adverse events (anginas, myocardial infarctions, heart failures, strokes, and cardiac deaths) in the future (adjusted HR =1.92; 95% CI: 1.10–3.13, for the fourth vs. first quartile). In the ROC analysis, the AUC for ApoB/A1 ratio was larger than that of Framingham Risk Score (0.604 vs. 0.543, p = 0.01) and TC/HDL-c (0.604 vs. 0.525, p < 0.01).

Conclusion: Our results suggest a significant association between ApoB/ApoA1 ratio and CHD severity and cardiovascular outcomes among patients with existing CHD and ApoB/A1 ratio demonstrated a better predictive accuracy for clinical outcomes compared with Framingham Risk Score and TC/HDL-c.

Keywords: Apolipoprotein B/A1 ratio, Coronary heart disease, Percutaneous coronary intervention

Introduction

Apolipoproteins (Apo) are the primary structural proteins for lipoprotein particles that guide lipid transportation and interact with specific receptors to facilitate uptake and deposition of lipids into tissue, and thus play a central role in cholesterol metabolism [1]. The apolipoproteinB (ApoB) is the main component of very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL) and lipoprotein (a); while ApoA1 represents the major high-density lipoproteins (HDL) Apo and is the main acceptor of cholesterol when HDL transports cholesterol from the tissues to the liver to be excreted from the body. In addition, ApoB and ApoA1 transport cholesterol from liver to cells [2]. The Apolipoprotein B/A1 ratio partially reflects the cholesterol balance between potentially atherogenic and anti-atherogenic lipoprotein particles. To date, several epidemiological
studies and clinical trials have suggested that high ApoB concentrations, low ApoA1 concentrations and the ApoB/A1 ratio may be better markers for the risk of coronary vascular disease (CVD) than LDL-c, HDL-c, and LDL-c/HDL-c ratio; and ApoB/A1 ratio found to be a useful predictors of cardiovascular events [3–8]. The INTERHEART study and many other previous studies also showed that the elevated ApoB/A1 ratio was a more powerful predictor than other traditional cardiovascular risk factors (including smoking, history of hypertension and diabetes mellitus, abdominal obesity, psychosocial factors, and dietary patterns) for metabolic disorders [9–11]. In concert with this, a post hoc analysis of data from 2 randomized controlled studies (the Treating to New Targets [TNT] study and the Incremental Decrease in End Points through Aggressive Lipid-Lowering [IDEAL] study) revealed that among serum lipid parameters, ApoB/A1 ratio has the strongest relationship with major cardiovascular outcomes in patients with established coronary heart disease [7]. Recently, Sarah et al. suggested that measurements of ApoB and ApoA1 were more informative about CVD risk than measurements of low-density lipoprotein cholesterol (LDL-c) and LDL-cholesterol (HDL-c); and at given levels of ApoB and ApoA1, HDL-c should not be considered to be an independent protective factor [12]. Quantitative evidence aside, whether Apolipoprotein B/A1 ratio is a marker for severity of coronary heart disease (CHD) or is involved in complex manifestations of coronary atheroma remains unknown. Therefore, the aim of our study was to examine the association between Apolipoprotein B/A1 ratio and atherosclerotic risk factors in CHD patients. We also investigated the association between Apolipoprotein B/A1 ratio and the number of vascular lesions, using the Gensini scores and the Framingham risk score as related to severity of CHD. Furthermore, we assessed the potential of Apolipoprotein B/A1 ratio as a marker to predict cardiovascular adverse events in a prospective cohort of Chinese CHD patients during a 5-year follow-up.

**Methods**

**2.1 Subjects**

A total of 2256 Han Chinese CHD cases were enrolled from hospitalized patients at Tongji Hospital and the Institute of Hypertension (Wuhan, China) between May 2009 and October 2014 (Table 1). The selection criteria, clinical and biochemical characteristics of the study subjects were described in detail in our previous report [13]. CHD was defined as one or more of the following diagnostic criteria: (1) > 50% stenosis in at least one of the major segments of coronary arteries (the right coronary artery, left circumflex, or left anterior descending arteries) assessed by coronary angiography; (2) World Health Organization criteria for elevated cardiac enzymes (troponin T, troponin I, creatine kinase-MB, aspartate aminotransferase, and glutamic pyruvic transaminase), typical ECG change (Minnesota Code 1.1 or 1.2 in ECG), and clinical symptoms; or (3) documented history of coronary artery bypass graft or percutaneous coronary intervention. Subjects with congenital heart disease,
cardiomyopathy, valvular disease, and renal or hepatic disease were excluded from the study.

The Gensini scoring system, which was established to define the severity of coronary stenosis [14], was also used for evaluating the coronary severity. The exact procedure was reported in our previous studies [13].

This study was approved by the Institutional ethics committees of the Tongji Hospitals, and written informed consents were obtained from all study participants.

Measurements
Anthropometric measurements including weight and height were taken with the participants wearing light clothing and no shoes. Body mass index (BMI) was calculated as the ratio of weight (kg) to the square of the height (m²). Blood pressure was measured with the participant in a seated position after 5 min of quiet rest. Blood tests were taken at the first time when the patients were hospitalized, and on participants fasting for at least four hours and the blood samples were collected into tubes containing 0.1% EDTA for immediate serum lipid analyses. Using fasting venous blood samples, we measured total cholesterol, HDL-c, TG, and LDL-c, on the Rocha modular DPP system according to standard procedures at the department of clinical chemistry, Tongji Hospital. Quantitative determination of ApoB and ApoA1 was done by nephelometry assays (Olympus Diagnostics, Japan).

Framingham risk score assessment
The Framingham risk score (FRS) was calculated from the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III algorithm, based on six coronary risk factors: gender, age, total cholesterol, HDL-cholesterol, systolic BP and smoking habit [15]. Among these factors, age, blood pressure, and cholesterol levels, were categorized according to their values and smoking status was classified as either “current smoker” or “non-smoker”. Finally, the corresponding points were assigned to each individual and the total score was used to reflect the individual’s CHD risk level.

Follow-up
In the present study, the primary outcome was the composite of all-cause death, stroke, myocardial infarction (MI), post-discharge revascularization (PCI/CABG), or unstable angina (UA) [16], according to the ACC/AHA cardiovascular endpoints data standards in clinical trials. The secondary end-point was event of first cardiovascular rehospitalization defined as visits to the hospital for angina-, arrhythmias-, or heart failure-related symptoms such as dyspnea and edema. The composite endpoint of cardiovascular adverse events were defined as the first occurrence of all-cause death, cardiac death, angina, new-onset/recurrent myocardial infarction, heart failure, repeat revascularization, stent thrombosis, or stroke/transient ischemic attack [17]. The follow-up information was obtained from a subset of 1639 patient during a 5-year follow-up, who were representative for the entire study population regarding baseline characteristics, by telephone or face to face interviews after the patients were discharged and the medicine treatments were also recorded at the same time. The patients who dropped out were excluded from the survival analysis because of an incomplete dataset or wrong phone numbers they had put on the medical records. Details regarding the information of the follow-up study were described in the previous reports [18, 19].

Statistical analysis
Statistical analyses were performed with SPSS 24.0 (SPSS Inc., Chicago, Ill) for Windows (Microsoft Corp, Redmond, Wash). The sample size in the present study was calculated by R studio (version 1.1.463) using “Hmisc” packages. For the prospective cohort, the event rate in the fourth quartile of plasma apoB/apoA1 ratios the was assumed to be 10, and 50% relative reduction of MACE risk in the first quartile. To achieve a power of 80% and allow for 10% losing to follow-up, 480 patients was needed in each quartiles. The sample size was calculated based on the primary end point for the CHD patients and we got a power of 0.95 to achieve the odds ratio (OR) of 1.6 for the risk of CHD. Assuming a percentage of poor responders of 5% at baseline, at least 275 patients were required (alpha and beta of 0.05). All continuous variables are expressed as mean ± standard deviation (mean ± SD). Categorical variables were presented as number and proportion (n, %). We used Spearman’s rank correlations to evaluate correlations between ApoB/ApoA1 ratio and cardiovascular risk factors among the CHD patients. The association between ApoB/ApoA1 ratio and Lipoprotein (Total Cholesterol/HDL-c) ratio, modified Gensini score and Framingham risk score were compared using multivariate linear regression analysis after adjustment for age, sex, BMI, smoking, drinking, hypertension and diabetes. We divided the distributions of ApoB/ApoA1 ratio and FRS among CHD patients into quartiles. The associations between the proportion of patients with 3-, 2-, 1-vessel disease and ApoB/ApoA1 ratio were compared using logistic regression analysis with adjustment for sex, age, drinking, hypertension, diabetes, smoking, and BMI in patients to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Linear trend p-values were derived by modeling the median value of each ApoB/ApoA1 ratio quartile as a continuous variable in adjusted models. To test the interaction between ApoB/ApoA1 ratio and subgroups in association with numbers of
vessel disease, we introduced a multiplicative interaction term and ApoB/ApoA1 ratio quartiles as continuous variables and added these variables to the aforementioned multivariate model. In the subgroup analyses, the predictive values of ApoB/ApoA1 ratio on outcomes during the 5-year follow-up period were analyzed by Cox proportional hazards models. Kaplan-Meier curves and Cox proportional hazards regression models were used to evaluate the associations of ApoB/ApoA1 ratio with adverse outcomes of CHD patients. The 95% confidence intervals (CIs) were computed from regression parameters. Three Cox-regression models were run as follows: without adjustment; adjusting for age, sex, and adjusting for age and sex as well as conventional clinical risk factors such as smoking, drinking, body mass index, hypertension, and diabetes; In the regression models, the ApoB/ApoA1 ratio was analyzed as categorical variables and the distributions of the ApoB/ApoA1 ratio among CHD subjects were divided into quartiles or tertils. Diagnostic accuracy of ApoB/ApoA1 ratio, FRS, and TC/HDL-c on a continuous scale in the prediction of clinical adverse outcomes of CHD was estimated as the area under the curve (AUC) from receiver operating characteristic curves. The diagnostic accuracies were determined to evaluate the ability of the 2 parameters to correctly discriminate between individuals with and without clinical outcomes. Equality of the AUC on the receiver operating curves was tested using the algorithm suggested by Delong et al. [20]. All diagrams were performed using Prism (GraphPad). All probability values were 2-sided, and a probability value less than 0.05 was considered statistical significance.

Results

3.1 ApoB/ApoA1 ratio and cardiovascular risk factors

The mean and standard deviation of ApoB/ApoA1 ratio in our study population was 0.79 ± 0.31 (Additional file 1: Figure S1). The correlation coefficients between the ApoB/ApoA1 ratio and the clinical variables are shown in Additional file 1: Table S1. The correlation coefficient (β) value with ApoB was 0.746, and with ApoA1 was −0.491. Among the clinical variables, HDL-c (β = −0.4), female sex (β = −0.101), and age (β = −0.137) showed a significant negative correlation with the ApoB/ApoA1 ratio, whereas LDL-c (β = 0.534), body mass index (BMI) (β = 0.128), systolic blood pressure (BP) (β = 0.79), total cholesterol (β = 0.414), and triglycerides (β = 0.205) were positively correlated with the ApoB/ApoA1 ratio. Based on the correlation analysis, age, sex, BMI, systolic BP, ApoB, ApoA1, current smoking, LDL-c, HDL-c, total cholesterol, and triglycerides were selected for multiple linear regression analysis. Of all the risk factors, the most informative model showed that total cholesterol, triglyceride, HDL-c, and LDL-c were found to be the main determinants of ApoB/A1 ratio.

Scatter plots displaying correlations between ApoB/A1 ratio and total cholesterol/HDL-c are shown in Additional file 1: Figure S2A. The ApoB/A1 ratio was positively correlated with total cholesterol/HDL-c (coefficient of determination: R² = 0.46, β ± SE = 0.15 ± 0.001, 95% CI: 0.007–0.013, p = 5.28 × 10⁻⁵) (Additional file 1: Figure S2A). A similar trend was seen between ApoB/A1 ratio and Framingham Risk Score (coefficient of determination: R² = 0.008, β ± SE = 0.08 ± 0.02, 95% CI: 0.008–0.086, p = 0.019) (Additional file 1: Figure S2B). However, the fit was poor, and the scatter was wide. The concentration of both LDL-c and TG increased across the tertiles of ApoB/ApoA1 ratio in our study (Additional file 1: Figure S3).

3.2 The association of ApoB/ApoA1 ratio with CHD disease severity

We explored whether the ApoB/A1 ratio was associated with vascular lesions and contributed to CHD severity as well. Table 2 presents logistic regression results for the number of vascular lesions associated with the ApoB/ApoA1 ratio categorized into quartiles according to the distribution in our population. In this multivariate model, trend tests remained significant, and adjusted ORs were significant for 2VD vs.1VD (OR = 1.71; 95% CI: 1.18, 2.49, for the fourth vs. first quartile; P_trend = 0.026), 3VD vs. 1VD (OR = 2.36; 95% CI: 1.65, 3.38; P_trend < 0.001), and 3VD vs. 1VD + 2VD (OR = 1.71; 95% CI: 1.28, 2.28; P_trend = 0.001) (Table 2). In the subgroup analysis, no clear differences were found in associations between numbers of vascular lesions and the ApoB/A1 ratio according to strata of age, smoking, drinking, and hypertension (Additional file 1: Figure S4). However, the significant effects were lost in subgroup of females, BMI ≥ 25, and diabetes. In the joint association analysis, significant interactions were found between 2VD vs.1VD and age (p = 0.003), BMI (p = 0.01), diabetes (p = 0.006) as well as smoking (p = 0.03). Furthermore, we found a significant association between the tertiles of ApoB/A1 ratios and gradually increased Gensini scores (p = 0.001) (Additional file 1: Figure S5A).

In the next analysis, the ApoB/A1 ratio was examined in complex conditions of cardiovascular and cerebrovascular disease manifestations including previous myocardial infarction, heart failure, and history of cerebrovascular disease. With an increasing number of the three cardio-cerebrovascular disease manifestations, the ApoB/A1 ratio gradually showed an increasing trend. However, this effect was not statistically significant (Additional file 1: Figure S5B).

3.3 ApoB/A1 ratio and cardiovascular adverse events in CHD patients

The prognostic value of ApoB/A1 ratio was evaluated in the prospective cohort of 1639 coronary heart disease
patients during a period of 5-year follow-up. During the follow-up period, there were 161 adverse events, including 17 unstable anginas, 22 myocardial infarctions, 20 heart failures, 16 strokes, and 86 deaths (47 cardiac deaths) in the study population. Figure 1 shows the unadjusted associations between the ApoB/A1 ratio and cardiovascular adverse events using the Kaplan-Meier curve method, stratifying the patients according to quartiles of ApoB/A1 ratios. Increasing ApoB/A1 ratio was marginally associated with increased cardiovascular outcomes compared with Framingham Risk Score and TC/HDL-c (0.604 vs. 0.543, \( p < 0.01 \)). ApoB/A1 ratio was treated as a continuous variable (Table 3). No significant associations were found between quartiles of TC/HDL-c and the outcome with or without adjustment for clinical covariates.

Multivariable Cox regression was performed to test whether the ApoB/A1 ratio was an independent risk predictor of cardiovascular outcomes (Table 3). Increasing quartiles of the ApoB/A1 ratio were found to be a significant predictor in the Cox-regression analysis and in a multivariate model after adjustment for conventional covariates (Q4 vs. Q1, adjusted HR =2.20; 95% CI: 1.08–3.56). Similar trends were found when the Framingham Risk Score was treated as a continuous variable (Table 3). No significant associations were found between quartiles of TC/HDL-c and the outcome with or without adjustment for clinical covariates.

ROC analysis for clinical outcomes at 5-year is shown in Fig. 1d. The 5-year clinical outcomes were predicted by ApoB/A1 ratio (AUC: 0.604, 95% CI: 0.550 to 0.659; \( P = 2.7 \times 10^{-4} \)) on a continuous scale using receiver operating characteristics curves. In the ROC analysis, the AUC for ApoB/A1 ratio was larger than that of Framingham Risk Score (0.604 vs. 0.543, \( p = 0.01 \)) and TC/HDL-c (0.604 vs. 0.525, \( p < 0.01 \)). ApoB/A1 ratio demonstrated a better predictive accuracy for clinical outcomes compared with Framingham Risk Score and TC/HDL-c.

### Table 2 Adjusted odds ratios [95% confidence interval (CI)] for coronary artery disease patients with the diagnosis determined by angiography according to quartiles of apoB/A1 ratios

| Quartiles of plasma apoB/apoAI ratios | Q1\((n = 567)\) | Q2\((n = 568)\) | Q3\((n = 565)\) | Q4\((n = 562)\) | p-Trend* |
|--------------------------------------|----------------|----------------|----------------|----------------|----------|
| 2VD Vs. 1VD (712Vs.683)              |                |                |                |                |          |
| Model 1                              | 1.00           | 1.14           | 1.03           | 1.35           | 0.32     |
| Model 2                              | 1.14           | 1.14           | 1.03           | 1.35           | 0.32     |
| Model 3                              | 1.14           | 1.14           | 1.03           | 1.35           | 0.32     |
| 3VD Vs. 1VD (867Vs.683)              |                |                |                |                |          |
| Model 1                              | 1.00           | 1.14           | 1.03           | 1.35           | 0.32     |
| Model 2                              | 1.14           | 1.14           | 1.03           | 1.35           | 0.32     |
| Model 3                              | 1.14           | 1.14           | 1.03           | 1.35           | 0.32     |
| 3VD Vs. 1VD + 2VD (867Vs.1395)       |                |                |                |                |          |
| Model 1                              | 1.00           | 1.14           | 1.03           | 1.35           | 0.32     |
| Model 2                              | 1.14           | 1.14           | 1.03           | 1.35           | 0.32     |
| Model 3                              | 1.14           | 1.14           | 1.03           | 1.35           | 0.32     |

*p-Trend across quartiles of ApoB/A1 ratios were obtained by including the median of each quartile as a continuous variable in logistic regression models. CI: confidence interval, Model 1, without adjustment; Model 2, adjusted for age, sex; Model 3, adjusted for the variables in Model 2 and BMI, Diabetes, Hypertension, Smoking, Drinking. 1VD = 1-vessel disease; 2VD = 2-vessel disease; 3VD = 3-vessel disease.

4. Discussion

The present study examined the ApoB/ApoA1 ratio, cardiovascular risk factors, and the severity of CHD in the Han Chinese population, and provided evidence of associations between the ratio and increased severity and poor prognosis of CHD. We found a significant positive correlation between ApoB/ApoA1 ratio and FRS and observed a significant association between ApoB/ApoA1 ratio and the number of vascular lesion and Gensini scores. The prospective cohort study showed that patients with higher ApoB/ApoA1 ratio had increased risk of developing multi-branch lesions and suffering more cardiovascular adverse events in the future.
In the last few decades, the association between elevated lipids levels and cardiovascular disease has been well-established. However, the extent to which components of blood lipids directly promote cardiovascular disease or represent a biomarker of risk has been debated, especially for the triglyceride and HDL-c [21, 22]. Several new markers have been introduced as alternative means to refine risk estimation beyond LDL-c from Friedewald’s formula in the presence of cardiovascular disease, such as non-HDL cholesterol, total cholesterol/HDL-c ratio, non-HDL cholesterol/HDL-c, and the apoB/apoA1 ratio [23, 24]. However, these results may have different effects in the prediction of dyslipidemia [25], cardiovascular disease [12], type 2 diabetes [26], MetS and insulin resistance [27], because the different types of lipid particles play different roles in lipid metabolism [12]. Therefore, as the ratios of cholesterol to apolipoprotein within LDL-c and within HDL-c particles vary, the positive associations of ApoB and of LDL-c with risk may differ, as may the inverse associations of apoA1 and of HDL-c with risk. On the other hand, almost all of the protein component of LDL-cholesterol is made up of ApoB, while ApoAI is important in removing excess cholesterol from tissues and incorporating it into HDL cholesterol for reverse transport to the liver, thus manifesting antiatherogenic effects [28]. The balance between proatherogenic and antiatherogenic lipoprotein particles, is a plausible way of characterizing cardiovascular risk independent of LDL-c levels. Now, routine measurement of apoB, apoA1, and their ratio ApoB/ApoA1 is widely available. In Western countries, high apoB and low apoA1 have been shown to be an
favorable Apo profile [31]. apolipoproteins B and A1 products have been found to be correlated with an un-
ing, obesity, low physical activity, low alcohol consump-
severity and prognosis of CHD in the Han Chinese
vided new evidence that ApoB/ApoA1 ratio predicts the
ratios in predicting CHD. In the present study, we pro-
global importance of a single measurement of this ratio,
INTERHEART case–control study [8] demonstrated the
control study [8] indicated 79) and was highly reproducible, with an intraclass
correlation coefficient of 0.81 between measurements on
samples taken a few years apart. Furthermore, the INTERHEART case–control study [8] demonstrated the
global importance of a single measurement of this ratio,
and reported it to be better than any cholesterol-based
ratios in predicting CHD. In the present study, we pro-
vided new evidence that ApoB/ApoA1 ratio predicts the
severity and prognosis of CHD in the Han Chinese
population.

Traditional cardiovascular risk factors such as smok-
ing, obesity, low physical activity, low alcohol consump-
tion and a diet high in sugar and low in fermented dairy
products have been found to be correlated with an un-
favorable Apo profile [31]. apolipoproteins B and A1 ra-
to has been widely used in predicting cardiovascular
risk in the European [32] and American population [4].
However, few evidence reported in the Asian. Our study
confirms prior results and found a significant correlation
between the ratio and the FRS which was based on six
coronary risk factors: gender, age, total cholesterol,
HDL-cholesterol, systolic BP, and smoking habit. Indeed,
almost all the parameters increased significantly in pa-
ents with 3-VD stenosis than in those in the 1VD

table 3 HR and 95%CI for multivariate-adjusted Analysis of the ApoB/apoA1 ratio, TC/HDL-c or Framingham Risk Score to Long-
term Clinical Outcomes

| Quartiles of plasma apoB/apoA1 ratios | Q1(n = 567) | Q2(n = 568) | Q3(n = 565) | Q4(n = 562) | 1-SD Increasing of Variablea |
|---------------------------------------|------------|------------|------------|------------|-----------------------------|
| ApoB/apoA1 ratio                      |            |            |            |            |                             |
| Model 1                               | 1          | 1.14 (0.66–1.88) | 1.12 (0.65–1.94) | 1.75 (1.09–2.95) | 1.55 (0.26–1.91) |
| Model 2                               | 1          | 1.15 (0.68–1.97) | 1.13 (0.65–1.97) | 1.91 (1.09–2.89) | 1.57 (1.28–1.93) |
| Model 3                               | 1          | 1.25 (0.69–2.23) | 1.31 (0.73–2.35) | 1.92 (1.10–3.13) | 1.59 (1.29–1.96) |
| Quartiles of TC/HDL-c                 |            |            |            |            |                             |
| TC/HDL-c                              | Q1(n = 566) | Q2(n = 568) | Q3(n = 563) | Q4(n = 565) |                             |
| Model 1                               | 1          | 0.82 (0.52–1.32) | 1.09 (0.70–1.69) | 1.21 (0.78–1.87) | 1.04 (0.89–1.23) |
| Model 2                               | 1          | 0.78 (0.48–1.25) | 1.03 (0.67–1.60) | 1.17 (0.76–1.81) | 1.03 (0.87–1.23) |
| Model 3                               | 1          | 0.90 (0.52–1.56) | 1.16 (0.64–2.11) | 1.27 (0.56–2.89) | 1.02 (0.85–1.22) |
| Quartiles of Framingham Risk Score    |            |            |            |            |                             |
| Framingham Risk Score                 | Q1(n = 457) | Q2(n = 721) | Q3(n = 603) | Q4(n = 481) |                             |
| Model 1                               | 1          | 1.04 (0.63–1.70) | 1.00 (0.60–1.67) | 1.60 (0.98–2.59) | 1.04 (0.98–1.09) |
| Model 2                               | 1          | 1.37 (0.80–2.36) | 1.56 (0.84–2.56) | 2.12 (1.06–3.02) | 1.11 (1.04–1.18) |
| Model 3                               | 1          | 1.34 (0.75–2.4) | 1.31 (0.67–2.57) | 2.20 (1.08–3.56) | 1.08 (1.01–1.15) |

HR hazard ratio, CI confidence interval. Model 1, without adjustment; Model 2, adjusted for age, sex; Model 3, adjusted for Model 2, BMI, Diabetes, Hypertension, Smoking, Drinking. *HR indicates hazard ratio for per each SD increase of ApoB/apoA1 ratio, TC/HDL-c or Framingham Risk Score.

Our data must be interpreted in the context of poten-
tial limitations. Given the cross-sectional nature of some
of our analyses (e.g., severity of CHD), the observed
association of different lipid ratios with CHD severity may
not be causal. Medication history, history of previous
medical or surgical diseases, duration of diabetes, or pos-
sible in tolerance to medications were ascertained retro-
spectively. The condition of some patients might not be
reliably assessed because of the uncertain interval from
index date to the exact day of medication discontinu-
ation, that is, the available data were only the time at
when medication was discontinued at each time point of
follow-up. Another limitation of the present study is we
were unable to compare predictive power of ApoB/
apoA1 ratio versus other ratios due to limited statistical power. Finally, it is important to confirm these findings in prospective cohort studies in other ethnic groups.

5. Conclusion
In conclusion, we found a significant association between ApoB/ApoA1 ratio and CHD severity and cardiovascular outcomes among patients with existing CHD. Our results strongly suggest the role of ApoB/ApoA1 ratio in the pathogenesis of CHD and these findings could potentially have significant clinical and public health implications.

Additional files

Additional file 1. Table S1. ApoB/A1 ratio with demographic characteristics and cardiovascular risk factors within CHD patients. Table S2. Multiple linear regression analysis of the apoB/A1 ratios as for important covariates. Figure S1. Histogram distribution of ApoB/A1 ratio in our population. Figure S2. Association between ApoB/A1 ratio and total cholesterol/HDL and Framingham Risk Score. Figure S3. Associations between tertiles of ApoB/A1 ratio and LDL and TG levels. Figure S4. Adjusted odds ratios [95% confidence interval (CI)] for coronary artery disease patients with the diagnosis determined by angiography according to quartiles of ApoB/A1 ratios in subgroups. Figure S5. Associations between tertiles of ApoB/A1 ratio and CHD disease severity.

Abbreviations
ApoA1: Apolipoprotein A1; ApoB: Apolipoprotein B; AUC: Area under the curve; BMI: Body mass index; CVD: Cardiovascular disease; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; ROC: Receiver operator characteristic curve; TC: Total cholesterol; TG: Triglyceride; CHD: Coronary heart disease; ORs: Odds ratios; CIs: Confidence intervals; FRS: Framingham risk score

Acknowledgements
We would like to thank Drs. Xunna Bao, Kun Miao, Jia Peng, and Luo Zhang for their efforts in recruiting patients and controls for this study. Kathy L. Brenner was acknowledged for skillful manuscript writing. We want to especially acknowledge all the participants in this study.

Disclosures
None.

Authors’ contributions
MT participated in the research design, carried out the epidemiological investigation, executed the cell experiment, undertook sequencing and performed statistical analyses. RL participated in the research design, collected the samples, and performed statistical analyses. GC-L drafted the manuscript, conceived the study, participated in the research design, collected the samples and edited the final manuscript. Z-LS, J-GJ and D-WW carried out the epidemiological investigation and collected samples. All authors have read and approved the final manuscript.

Funding
This work was supported by grants from the National Natural Science Foundation of China (81770351) and the Hubei Chenguang Talented Youth Development Foundation (0106540056).

Availability of data and materials
The original data used to support the findings of this study are available from the corresponding author upon request.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication
Informed consent was obtained from all individual participants included in the study.

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. 2Hubei Province Key Laboratory of Genetics and Molecular, Mechanisms of Cardiological Disorders, Wuhan 430030, China. 3Department of Nutrition and Department of Epidemiology, Harvard T.H. Chan, School of Public Health, Boston, MA, USA.

Received: 27 February 2019 Accepted: 31 October 2019
Published online: 19 November 2019

References
1. Bolanos-Garcia VM, Miguel RN. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Prog Biophys Mol Biol. 2003;83(1):47–68.
2. Talmud PJ, Hare E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Atherosclerosis. 2002;221(1):1918–23.
3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.
4. Siirea-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohvik J, et al. Concentration of apolipoprotein B is comparable with the apoB/apoA-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J. 2009;30(6):710–7.
5. Sniderman AD, Jungner I, Junger I, Holme L, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA1 ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med. 2006;259(5):455–61.
6. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112–23.
7. Kasteleijn JP, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117(23):3002–9.
8. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman AD, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224–33.
9. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 4 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36(6):1758–64.
10. Janghorbani M, Amini M. Utility of serum lipid ratios for predicting incident type 2 diabetes: the Isfahan diabetes prevention study. Diabetes Metab Res Rev. 2016;32(6):572–80.
11. Hwang Y-C, Ahn H-Y, Park S-W, Park C-Y. Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study. Acta Diabetol. 2014;51(4):541–6.
12. Parish S, Peto R, Palmer A, Clarke R, Lewington S, Ofer A, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J. 2009;30(11):2137–46.
13. Cui G, Li Z, Li R, Huang J, Wang H, Zhang L, et al. A functional variant in APOA5/A4/A1 gene cluster contributes to elevated triglycerides and severity of CAD by interfering with microRNA 3201 binding efficiency. J Am Coll Cardiol. 2014;64(3):267–77.

14. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(16):606.

15. Steinberg DL. ACP journal Club. Novel risk markers improved Framingham risk score cardiovascular event prediction in intermediate-risk adults. Ann Intern Med. 2012;157(12):JC6–13.

16. Hicks KA, Tcheng JE, Bookert B, Chaitman BR, Cutlip DE, Farb A, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards). J Nucl Cardiol. 2015;22(5):1041–144.

17. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51.

18. Li C, Sun Y, Shen X, Yu T, Li Q, Ruan G, et al. Relationship Between β-Blocker Therapy at Discharge and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2016;5(11):1-14.

19. Li C, Zhang L, Wang H, Li S, Zhang Y, You L, et al. Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention - a multicenter study. Int J Cardiol. 2017;240:360–6.

20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.

21. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–333.

22. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol. 2010;55(13):1283–99.

23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.

24. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112(22):3375–83.

25. Tognon G, Berg C, Mehlig K, Thelle D, Strandhagen E, Gustavsson J, et al. Comparison of apolipoprotein (apoB/apoA-I) and lipoprotein (total cholesterol/HDL) ratio determinants. Focus on obesity, diet and alcohol intake. PLoS ONE. 2012;7(7):e40878.

26. Mao Y, Yu Y, Lu L. The nonlinear association between apolipoprotein B to apolipoprotein A1 ratio and type 2 diabetes. Medicine (Baltimore). 2017;96(1):e5834.

27. Kim SW, Jee JH, Kim HJ, Suh S, Bae JC, et al. Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1. Int J Cardiol. 2013;168(3):2678–83.

28. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and nutrition examination survey III (NHANES III). Clin Chem. 1997;43(12):2364–78.

29. Waldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358(9289):2026–33.

30. Raitakari OT, Mäkinen V-P, McQueen MJ, Niemi J, Juvanala M, Jauhiainen M, et al. Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk. Atherosclerosis. 2013;226(1):245–51.